A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

Lenalidomide, which is used to treat myelodysplastic syndrome, kills mutation-bearing hematopoietic cells by increasing expression of the G-protein-coupled receptor GPR68, leading to increased intracellular calcium concentrations and calpain activation.